Inventory: A selection of Blod research on September 3, 2020.

Prognostic studies of COVID-19-in-patients-with-CLL-a' target-'_blank' rel'noopener';https://doi.org/1 10.1182/blood.2020006965 Taking into account old age, co-merger and immunodeficiability disorders, CLL patients have a higher risk of infection with neo-coronary pneumonia, while coronavirus-19 disease (COVID-19)-related prognosis is poor.
researchers recently analyzed symptomatic CLL patients (n-198) who were diagnosed with COVID-19 infection at 43 international centers.
hospitalization rate was 90 per cent for 198 patients.
age of confirmed COVID-19 infection was 70.5 years.
the average CIRS score is 8.
39% of patients were initially treated (observation and waiting) and 61% received at least one CLL treatment (on average twice).
90 (45%) patients, mostly BTK inhibitors (BTKi, 76%), were receiving CLL treatment when they were diagnosed with COVID-19.
follow-up for 16 days, the overall death rate (CFR) was 33%.
the probability of hospitalization, ICU, intestion and death for COVID-19 in patients with primary treatment and previous treatment was similar, at 89% vs 90%, 35% vs 36%, 33% vs 25% and 37% vs 32%, respectively.
BTKi treatment CLL at the time of diagnosis of COVID-19 does not affect the survival of the patient (CFR: 34% vs 35%).
2: Arginine synthesis enhances the proliferation and anti-tumor efficacy of CAR-T cells https://doi.org/10.1182/blood.20190045000 affected by tumor metabolism, the level of arginine in tumor microenvironment decreased, and the lower arginine microenvironment is not conducive to the proliferation of cells of the chimic antigen-insular T-cell (CAR-T), limiting its clinical efficacy.
studies have confirmed that arginine resynthetic amino acidase (ASS) and birdine transaminase (OTC) are lowly expressed in T-cells, which are susceptible to the effects of the arginine microenvironment.
researchers recently found that T cells can be reprogrammed to express functional ASS or OTC enzymes to work with different chilayer antigens.
modification can increase car-T cell proliferation without affecting the cytotoxicity of CAR cells or increasing fatigue.
in the body, enzyme-modified CAR-T cells can increase the removal rate of leukemia or solid tumor load.
: The effects of DHFR and FPGS embryo mutations on methotrexate metabolism and all recurrence risk https://doi.org/10.1182/blood.2020005064 methotrexate (MTX) maintenance therapy is critical to the treatment of acute lymphoblastic leukemia (ALL), but appropriate treatment dose choices due to individual differences remain a challenge.
to evaluate genetic factors associated with MTX metabolism, the researchers analyzed the genome-wide association of 447 ALL cases in the 'Nordic Society for Paediatric Haematology and Oncology ALL2008' study and validated them in a separate queue of 196 patients.
study found that an intergene SNP (rs1382539) located on the original regulation of the DHFR gene was associated with elevated levels of short-chain methotrexate polyglutamate by inhibiting enhanced child activity, while rs35789560 (p.R466C) on FPGS was associated with reduced levels of long-chain methotrexate glutamate by reducing catalytic activity.
addition, the FPGS variant is associated with an increased risk of ALL recurrence.
. hematocytosis (CGD) is a primary immunodeficiency disease that can lead to life-threatening infections and inflammatory complications.
allo-HCT is acceptable to allo-HCT patients, but the signs of transplantation remain controversial.
researchers recently conducted a multi-center retrospective study that analyzed 712 CGD patients who had allo-HCT transplants at the EBMT Center from 1993 to 2018.
712 CGD patients, including 635 children and 77 adults.
follow-up for 45 months.
age at the time of transplantation was 7 years (range 0.1-48.6 years).
Kaplan-Meier estimates for OS and EFS for three years were 85.7 per cent and 75.8 per cent, respectively.
in MVA, the decrease in older than survival was related to an increase in the risk of chronic GVHD.
although the three-year OS and EFS in adult patients were 76% and 69%, respectively.
the use of an antigen misalmed supply is associated with lower OS and EFS.
in a small group of patients who received more than one supply-source hematocyte transplant from mismatched antigens, there was no significant difference in OS, but EFS is now lower (HR 3.69).
of a conditioning scheme does not affect OS or EFS.
source: MedSci Originals !-- content presentation ends -- !-- to determine whether the login ends.